kidney disease news from FierceBiotech

In an effort to streamline its business and save cash, Pharmacopeia is laying off 15 percent of its workforce and decreasing "other expenses through improved operational efficiencies and increased... Read more...

If you've been pondering the best way to set up your biotech company's corporate retreat, consider the case of Dr. Brian Pereira, the CEO of Amag Pharmaceuticals, which is developing an iron... Read more...

Japan's Takeda has walked away from development of its once-promising cholesterol drug TAK-475. The first sign of... Read more...

Keryx Biopharmaceuticals' stock price wiped out this morning on the rocky shores of a failed late-stage trial of its lead drug, Sulonex, for diabetes. The news landed in a market that has little... Read more...

Researchers for Shire say that the chronic kidney disease drug Fosrenol failed to hit its primary endpoint in a mid-stage study. The primary endpoint focused on the control of serum phosphate to... Read more...

> Schering-Plough says that a mid-stage trial of its experimental oral thrombin receptor antagonist (TRA) demonstrated that the therapy was safe and did not increase major or minor bleeding in... Read more...

Exelixis is reporting that one of its experimental therapies for diabetic nephropathy failed to hit its primary endpoint in Phase II. The kidney disease is brought on by chronic diabetes. Researchers... Read more...

> Advanced Magnetics has announced preliminary positive results from its fourth and final planned Phase III clinical trial of ferumoxytol as an intravenous iron replacement therapeutic in chronic... Read more...

Press Release: Osprey Pharmaceuticals Limited Secures $9 Million In Financing

... Read more...

Ception Therapeutics has rounded up $63 million in its third round of venture capital, with Essex Woodlands Health Ventures leading the way. Ception, which is based in Malvern Hill, PA, says that much of that money will be used to advance a late-stage biologic compound in clinical development for multiple inflammatory conditions, a small molecule anti-TNF program and other discovery programs. Investor Growth Capital, MDS Life Sciences Technology Fund II, New Science Ventures and Aperture …

... Read more...